

EASL HCC SUMMIT 2018

FROM BASIC TO CLINICAL RESEARCH:

HOW TO IMPROVE HCC CLINICAL CARE?

01 – 03, MARCH 2018

GENEVA, SWITZERLAND

SCIENTIFIC ORGANISING COMMITTEE

Alejandro Forner, *Spain*

Peter Galle, *Germany*

Jessica Zucman-Rossi, *France*

PRELIMINARY* PROGRAMME

Thursday 01 March 2018

15:00 – 15:15

Welcome and introduction

Session I: HCC in 2018 – Which are the pressing issues?

Chairs:

Alejandro Forner, *Spain*

Peter Galle, *Germany*

15:15 – 15:45

The changing epidemiology of HCC – how do we identify and screen patients at risk?

Jean-François Dufour, *Switzerland*

15:45 – 16:15

Tumour biology – stroma – immune cells – where are the best targets?

Jessica Zucman-Rossi, *France*

16:15 – 16:45

Immunotherapy in HCC and the hepatologist – what does the future multidisciplinary team look like?

Jordi Bruix, *Spain*

16:45 – 17:15

Coffee break and ePoster session I

*Subject to change

Session 2: From tumour diversity to individualised management

Chairs: Massimo Colombo, *France*
Sabine Werner, *Switzerland*

- 17:15 – 17:45 **Genomic diversity in HCC: The TCGA experience**
Lewis Roberts, *United States*
- 17:45 – 18:15 **Mutational signatures in HCC resulting from exogenous and endogenous exposure**
Eric Letouzé, *France*
- 18:15 – 18:45 **What is unique about fatty-liver-associated HCC?**
Helen Reeves, *United Kingdom*
- 18:45 – 19:15 **Debate: DAA treatment of cirrhotic HCV infected patients with HCC – pro/con**
Pro: Antonio Craxi, *Italy*
Con: Xavier Forns, *Spain*
Discussion
- 19:15 *Cocktail reception and ePoster session 2*

Friday 02 March 2018

Session 3: Intratumoural heterogeneity and mechanisms of therapy resistance

Chairs: Helen Reeves, *United Kingdom*
Jessica Zucman-Rossi, *France*

- 08:00 – 08:30 **Single cell approaches to study resistance in PLC2- The cell of origin in HCC and CCA**
TBC
- 08:30 – 09:00 **Diagnostic and prognostic role of circulating microparticles in hepatobiliary cancers**
Miroslaw Kornek, *Germany*
- 09:00 – 09:30 **Liquid biopsy for patient management: Lesson from colon cancer**
Pierre Laurent-Puig, *France*
- 09:30 – 10:00 **Extent of intratumoural genomic diversity**
Augusto Villanueva, *United States*
- 10:00 – 10:30 *Coffee Break and ePoster session 3*

*Subject to change

Session 4: From molecular defects to new targeted therapies in HCC

Chairs: Josep Llovet, *Spain*
Tom Luedde, *Germany*

- 10:30 – 10:50 **Telomerase activation**
Jean-Charles Nault, *France*
- 10:50 – 11:10 **WNT/ β -catenin activation**
Sabine Colnot, *France*
- 11:10 – 11:30 **NRF2 in liver carcinogenesis**
Sabine Werner, *Switzerland*
- 11:30 – 11:50 **Transcriptional regulators in hepatocarcinogenesis-key integrators of malignant transformation**
Kai Breuhahn, *Germany*
- 11:50 – 12:10 **FGF axis and FGFR inhibitors**
TBD
- 12:10 – 12:30 **Roundtable discussion: Translatability of results from animal models**
- 12:30 – 13:30 **Lunch break and ePoster session 4**

Session 5: Early diagnosis of HCC: Which is the best strategy?

Chairs: Carmen Ayuso, *Spain*
Fabio Piscaglia, *Italy*

- 13:30 – 13:40 **Tumour board #1: Clinical case presentation**
Jordi Rimola, *Spain*
- 13:40 – 14:00 **Is there a role for Contrast Enhanced Ultra Sound (CEUS) for improving the diagnostic accuracy of imaging techniques? The hepatologist view**
Fabio Piscaglia, *Italy*
- 14:00 – 14:20 **How to best diagnose HCC? Do we need hepatobiliary MR contrast agents? The radiologist view**
Christophe Aubé, *France*
- 14:20 – 14:40 **Is biopsy adding clinically relevant information? The pathologist view**
Valérie Paradis, *France*
- 14:40 – 15:00 **Tumour board #1: Clinical case discussion**

*Subject to change

Session 6: Scores and biomarker

Chairs: Phil Johnson, *United Kingdom*
Franco Trevisani, *Italy*

- 15:00 – 15:20 **What is the role of biomarkers in diagnosis, prognosis and surveillance?**
Franco Trevisani, *Italy*
- 15:20 – 15:50 **Development of tumour makers for diagnosis, prognosis and tumour response prediction**
Josep Llovet, *Spain*
- 15:50 – 16:10 **What is the added value of clinical scoring systems?**
Phil Johnson, *United Kingdom*
- 16:10 – 16:30 **Roundtable discussion: How we can improve the current staging systems?**
- 16:30 – 17:00 **Coffee break and ePoster session 5**

Session 7: Curative treatment of HCC: A multidisciplinary management

Chairs: Pietro Majno, *Switzerland*
Vincenzo Mazzaferro, *Italy*

- 17:00 – 17:10 **Tumour board #2: Clinical case presentation**
Pietro Majno, *Switzerland*
- 17:10 – 17:40 **Expanding boundaries of surgical resection in HCC**
Pietro Majno, *Switzerland*
- 17:40 – 18:10 **Locoregional therapies in HCC: Ablation, transarterial therapies or combination of both?**
Rita Golfieri, *Italy*
- 18:10 – 18:40 **Liver transplantation – How to optimize patient selection?**
Vincenzo Mazzaferro, *Italy*
- 18:40 – 19:00 **Tumour board #2: Clinical case discussion**

*Subject to change

Saturday 03 March 2018

08:00 – 08:20 **Introduction – Current Status of the EASL Clinical Practice Guidelines on HCC**
Peter Galle, *Germany*

Session 8: Advanced HCC: A multidisciplinary approach

Chairs: Bruno Sangro, *Spain*
Valerie Vilgrain, *France*

08:20 – 08:30 **Tumour board #3: Clinical case presentation**
Markus A Wörns, *Germany*

08:30 – 09:00 **Approved systemic treatments for HCC: Which is the best treatment approach?**
Maria Reig, *Spain*

09:00 – 09:30 **Assessment of systemic treatment activity by imaging**
Carmen Ayuso, *Spain*

09:30 – 09:50 **Tumour board #3: Clinical case discussion**

10:00 – 10:30 *Coffee break and ePoster session 6*

Session 9: Immune system and HCC: potential role of immunotherapy

Chairs: Massimo Colombo, *Italy*
Markus A Wörns, *Germany*

10:30 – 10:50 **Inflammation in liver tumorigenesis: Potential targets for immunotherapy**
Eli Pikarsky, *Israel*

10:50 – 11:10 **Role of immunology in HCC development and progression**
Pablo Sarobe, *Spain*

11:10 – 11:40 **Immunotherapy in HCC: Current evidence and future perspective**
Bruno Sangro, *Spain*

11:40 – 12:30 **Roundtable discussion: Novel approaches in immunotherapy**

12:30 – 13:30 *Lunch break and ePoster session 7*

*Subject to change

Session 10: Future perspectives in HCC

Chairs: Jordi Bruix, *Spain*
Sandrine Faivre, *France*

13:30 – 13:50

Screening for new drugs
Lars Zender, *Germany*

13:50 – 14:10

Patient-derived models for drug discovery in liver cancer
Jens Marquardt, *Germany*

14:10 – 14:40

What have we learn from failed trials and how do we design future trials?
Sandrine Faivre, *France*

14:40 – 15:00

Future perspectives in HCC: The industry perspective
TBC

15:00 – 15:30

Round table discussion: Needs in the management of HCC and opportunities for the future

*Subject to change